Logo image of ONC

BEIGENE LTD-ADR (ONC) Stock Fundamental Analysis

NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD

230.98  +2.84 (+1.24%)

After market: 230.98 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ONC. ONC was compared to 568 industry peers in the Biotechnology industry. ONC may be in some trouble as it scores bad on both profitability and health. ONC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ONC has reported negative net income.
In the past year ONC has reported a negative cash flow from operations.
In the past 5 years ONC always reported negative net income.
In the past 5 years ONC always reported negative operating cash flow.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -2B -4B -6B -8B -10B

1.2 Ratios

Looking at the Return On Assets, with a value of -15.97%, ONC belongs to the top of the industry, outperforming 82.22% of the companies in the same industry.
ONC has a Return On Equity of -26.99%. This is amongst the best in the industry. ONC outperforms 80.28% of its industry peers.
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

ONC has a Gross Margin of 83.13%. This is amongst the best in the industry. ONC outperforms 85.92% of its industry peers.
In the last couple of years the Gross Margin of ONC has remained more or less at the same level.
ONC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B 50B

2.2 Solvency

ONC has an Altman-Z score of 4.87. This indicates that ONC is financially healthy and has little risk of bankruptcy at the moment.
ONC has a Altman-Z score of 4.87. This is amongst the best in the industry. ONC outperforms 81.69% of its industry peers.
ONC has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.31, ONC is doing worse than 71.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 4.87
ROIC/WACCN/A
WACC10.28%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10B -10B 20B 30B

2.3 Liquidity

ONC has a Current Ratio of 1.94. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
ONC's Current ratio of 1.94 is on the low side compared to the rest of the industry. ONC is outperformed by 76.06% of its industry peers.
ONC has a Quick Ratio of 1.72. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.72, ONC is not doing good in the industry: 78.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.72
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.52% over the past year.
EPS 1Y (TTM)21.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1260.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%73.88%

3.2 Future

The Earnings Per Share is expected to grow by 102.66% on average over the next years. This is a very strong growth
Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 18.74% on average per year.
EPS Next Y109.55%
EPS Next 2Y64.57%
EPS Next 3Y50.96%
EPS Next 5Y102.66%
Revenue Next Year35.78%
Revenue Next 2Y27.53%
Revenue Next 3Y23.15%
Revenue Next 5Y18.74%

3.3 Evolution

ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K 2.5K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ONC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 382.26, the valuation of ONC can be described as expensive.
Based on the Price/Forward Earnings ratio, ONC is valued cheaply inside the industry as 90.14% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ONC to the average of the S&P500 Index (21.08), we can say ONC is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 382.26
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ONC's earnings are expected to grow with 50.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y64.57%
EPS Next 3Y50.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEIGENE LTD-ADR

NASDAQ:ONC (4/17/2025, 8:00:02 PM)

After market: 230.98 0 (0%)

230.98

+2.84 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-07 2025-05-07
Inst Owners26.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap24.89B
Analysts81.67
Price Target281.37 (21.82%)
Short Float %31.58%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP-2.03%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-414.4%
Min EPS beat(2)-805.99%
Max EPS beat(2)-22.81%
EPS beat(4)0
Avg EPS beat(4)-490.89%
Min EPS beat(4)-999.2%
Max EPS beat(4)-22.81%
EPS beat(8)1
Avg EPS beat(8)-245.79%
EPS beat(12)2
Avg EPS beat(12)-169.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.14%
Min Revenue beat(2)0.26%
Max Revenue beat(2)28.03%
Revenue beat(4)4
Avg Revenue beat(4)14.41%
Min Revenue beat(4)0.26%
Max Revenue beat(4)28.03%
Revenue beat(8)8
Avg Revenue beat(8)17.43%
Revenue beat(12)11
Avg Revenue beat(12)13.57%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.05%
PT rev (3m)N/A
EPS NQ rev (1m)-0.57%
EPS NQ rev (3m)-16.73%
EPS NY rev (1m)-16.76%
EPS NY rev (3m)25.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 382.26
P/S 7.67
P/FCF N/A
P/OCF N/A
P/B 7.51
P/tB 7.79
EV/EBITDA N/A
EPS(TTM)-6.33
EYN/A
EPS(NY)0.6
Fwd EY0.26%
FCF(TTM)-10.42
FCFYN/A
OCF(TTM)-5.38
OCFYN/A
SpS30.12
BVpS30.74
TBVpS29.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.13%
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 16.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.72
Altman-Z 4.87
F-Score4
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.9%
Cap/Sales(5y)29.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1260.99%
EPS Next Y109.55%
EPS Next 2Y64.57%
EPS Next 3Y50.96%
EPS Next 5Y102.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%73.88%
Revenue Next Year35.78%
Revenue Next 2Y27.53%
Revenue Next 3Y23.15%
Revenue Next 5Y18.74%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.03%
EBIT Next 3Y35.16%
EBIT Next 5Y29.35%
FCF growth 1Y33.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.76%
OCF growth 3YN/A
OCF growth 5YN/A